¹⁷⁷Lu-PSMA radio-ligand therapy

Lutetium-177-labeled PSMA radio-ligand therapy is becoming more and more widespread in nuclear medicine departments, in France and around the world. Practitioners must master specificities of this treatment in order to develop this type of therapeutic care in the best conditions. This summary article presents the methods of carrying out treatment with Lu-177-PSMA in nuclear medicine departments as well as the various current clinical research subjects concerning this theme. (C) 2023 Elsevier Masson SAS. All rights reserved.